legal
J&J Talc Verdicts Top $2.5B in 2025
Johnson & Johnson faced over $2.5 billion in talc-related jury verdicts in 2025, including the largest individual award in litigation history.
2025 News Archive
29 articles
December 2025
news
Mesothelioma Treatment Advances: 2025
2025 saw major mesothelioma treatment advances including TEAD inhibitors, bispecific antibodies, and perioperative immunotherapy. Here's the full review.
legal
Record $1.56B Verdict Against J&J in Talc
A Baltimore jury awarded $1.56 billion to Cherie Craft, a Maryland woman who developed mesothelioma after 40+ years of using Johnson & Johnson baby powder.
legal
$65.5M Verdict Against J&J in Minnesota Mesothelioma Case
A Minnesota jury awarded $65.5 million to a mother of three who developed mesothelioma after childhood exposure to Johnson & Johnson baby powder.
legal
$40M Verdict Against J&J in California Ovarian Cancer Case
Los Angeles jury awards $40 million to two women who developed ovarian cancer after decades of using Johnson & Johnson talc-based body powders.
research
Drug Combo Achieves 60% Response Rate
A Dutch trial found two drugs achieved a 60% response rate in mesothelioma patients whose cancer returned after immunotherapy.
November 2025
news
FDA Withdraws Talc Asbestos Testing Rule
FDA withdrew its rule requiring asbestos testing in cosmetic talc. Public health advocates warn of ongoing contamination risks.
treatment
Novartis Halts Mesothelioma Drug, Rival Advances
Novartis halted its experimental mesothelioma drug IAG933, but a competitor's TEAD inhibitor shows strong results in clinical trials.
research
Cyncado to Test TT-4 in Australian Meso Trial
An Australian trial will test Cyncado's TT-4 A2B receptor antagonist in ~50 people with mesothelioma after first-line therapy.
legal
Judge Allows Experts in 67,500 Talc Cases
Special master approves expert testimony in 67,500 J&J talc lawsuits, clearing the path for federal trials in ovarian cancer cases.
exposure
Japan Banned Asbestos in 2006, Cases Rise
Despite banning asbestos in 2006, Japan sees 1,500+ mesothelioma deaths yearly. The country's experience shows why bans alone aren't enough.
October 2025
exposure
Minot AFB Missile Crews Face Asbestos Risk
A 2025 federal study found missile alert facility workers at Minot AFB have increased cancer risk from asbestos in Cold War-era underground bunkers.
research
Mesothelioma Survival: 18-Year Survivor's Story
Diagnosed with peritoneal mesothelioma at 21 while pregnant, Tamron Little shares her 18-year journey and the reality of long-term survivorship.
legal
$966M Verdict: J&J Concealed Talc Asbestos Risk
An LA jury awarded $966 million to the family of Mae Moore, an 88-year-old who died from mesothelioma after using Johnson & Johnson baby powder daily.
legal
$966M Verdict Against J&J in California Mesothelioma Case
A Los Angeles jury awarded $966 million to the family of Mae Moore, 88, who died from mesothelioma after lifelong use of Johnson's Baby Powder.
September 2025
news
Mesothelioma Awareness Day: September 26
September 26 is Mesothelioma Awareness Day. Learn about the history of awareness efforts, current statistics, and how to get involved.
research
Mesothelioma Treatment: Hopkins Immunotherapy Trial
Johns Hopkins phase 2 trial shows pre- and post-surgery immunotherapy is safe and effective for operable mesothelioma, with 28.6-month median survival.
treatment
VT3989 Doubles Time Without Progression
Patients on VT3989 went 40 weeks without cancer progression. Vs. 15 weeks on standard chemo. FDA granted Fast Track status.
treatment
Hopkins: Pre-Surgery Immunotherapy Success
A Johns Hopkins trial found that immunotherapy before and after surgery extended median survival to 28.6 months, 10 months longer than average.
treatment
Trial Tests Immunotherapy Before Surgery
Baylor and Duke are testing immunotherapy before surgery for mesothelioma. Trial now enrolling operable patients.
research
IMPALA Trial: Light Therapy for Mesothelioma
The IMPALA trial in France is testing intrapleural photodynamic therapy combined with nivolumab for inoperable mesothelioma. Results expected mid-2026.
August 2025
legal
$3.3M Ford Asbestos Brake Verdict Upheld in NY
A New York appeals court upheld a $3.3M verdict against Ford after a former dealership worker was diagnosed with peritoneal mesothelioma from brake dust.
exposure
Paramount Studios Faces Asbestos Suits
Paramount Studios faces lawsuits alleging asbestos exposure on film sets and soundstages. The entertainment industry has a hidden asbestos history.
July 2025
legal
$117M Asbestos Verdict Sets New York Record
A jury awarded $117M to a sheet metal worker exposed to asbestos at the original World Trade Center, the largest such verdict in New York history.
news
Asbestos Disclosure Bill H.R.4247
H.R.4247 would require sellers and landlords to disclose known asbestos hazards before completing sales or leases of residential properties.
June 2025
treatment
Dual-Target Immunotherapy Shows 52% Response
BioNTech's dual-target immunotherapy achieved a 52% response rate in people with mesothelioma. Results presented at ASCO 2025.
news
UK Commits £1.2B for Asbestos Removal
UK government allocates £470 million for 656 schools and £750 million for NHS sites to address asbestos, crumbling infrastructure in 2025-2026.
February 2025
exposure
Canada Banned Asbestos, Cases Still Rise
Despite banning asbestos, Canada sees 472 mesothelioma deaths annually. Legacy asbestos in buildings and the disease's long latency explain the trend.
January 2025
treatment
FDA Approves Opdivo Qvantig for Mesothelioma
FDA approval of Opdivo Qvantig allows subcutaneous nivolumab delivery in under 5 minutes, compared to 30-minute IV infusions for people with mesothelioma.